NCT07285226 Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study
| NCT ID | NCT07285226 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Center for Health Sciences, Serbia |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.
Eligibility Criteria
Inclusion Criteria: * Age \> 60 years * Low muscle strength by handgrip (SDOC criteria for sarcopenia): \< 35.5 kg in men and \< 20 kg in women * Sign free and informed consent * Demonstrate interest, conditions and availability to participate Exclusion Criteria: * Patients undergoing interventional treatment for sarcopenia * Physical amputation * Cognitive impairment (MSSE \< 25) * Unwillingness to return for follow-up analysis * Participation in other clinical trials
Contact & Investigator
Sergej Ostojic, MD, PhD
STUDY CHAIR
Center for Mitochondrial Medicine
Frequently Asked Questions
Who can join the NCT07285226 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07285226 currently recruiting?
Yes, NCT07285226 is actively recruiting participants. Contact the research team at sergej.ostojic@chess.edu.rs for enrollment information.
Where is the NCT07285226 trial being conducted?
This trial is being conducted at Belgrade, Serbia.
Who is sponsoring the NCT07285226 clinical trial?
NCT07285226 is sponsored by Center for Health Sciences, Serbia. The principal investigator is Sergej Ostojic, MD, PhD at Center for Mitochondrial Medicine. The trial plans to enroll 30 participants.